In-person presentation titled ‘Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutics’ to take place on June 7 in Park City, Utah Dr. Christoph Bausch to. | May 31, 2022
SAB Biotherapeutics (NASDAQ:SABS – Get Rating) and BioCardia (NASDAQ:BCDA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership. Analyst Ratings This is a summary of current ratings and […]
SAB Biotherapeutics (NASDAQ:SABS – Get Rating) had its price target trimmed by Chardan Capital from $17.00 to $10.00 in a research report sent to investors on Friday, The Fly reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also issued reports on SABS. Northland Securities raised their target price […]